Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: A paradigm for faster assessment of new antituberculosis drugs

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3197-3204

  Gumbo, Tawanda ^a   Dona, Chandima S W Siyambalapitiyage ^a   Meek, Claudia ^b   Leff, Richard ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GROWTH RATE; IN VITRO STUDY; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE;

EID: 67749118211     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01681-08     Document Type: Article

References (60)

1. Aly, S., K. Wagner, C. Keller, S. Malm, A. Malzan, S. Brandau, F. C. Bange, and S. Ehlers. 2006. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J. Pathol. 210:298-305.
2. Anonymous. 1981. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet i:171-174.
3. Bilello, J. A., G. Bauer, M. N. Dudley, G. A. Cole, and G. L. Drusano. 1994. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob. Agents Chemother. 38:1386-1391.
4. Blaser, J., B. B. Stone, and S. H. Zinner. 1985. Two compartment kinetic model with multiple artificial capillary units. J. Antimicrob. Chemother. 15(Suppl. A):131-137.
5. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
6. Bonate, P. L. 2000. Clinical trial simulation in drug development. Pharm. Res. 17:252-256.
7. Boshoff, H. I., V. Mizrahi, and C. E. Barry III. 2002. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J. Bacteriol. 184:2167-2172.
8. Brindle, R., J. Odhiambo, and D. Mitchison. 2001. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm. Med. 1:2.
9. Canetti, G. 1955. The tubercle bacillus in the pulmonary lesion of man. Springer Publishing Company, New York, NY.
10. Centers for Disease Control and Prevention. 2006. Reported tuberculosis in the United States, 2005. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA. http://www.cdc.gov/tb/surv/surv2005/PDF/TBSurvFULLReport.pdf (accessed 4 October 2008).
11. Cheng, S. J., L. Thibert, T. Sanchez, L. Heifets, and Y. Zhang. 2000. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother. 44:528-532.
12. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Conte, J. E., Jr., J. A. Golden, S. Duncan, E. McKenna, and E. Zurlinden. 1999. Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43:1329-1333.
14. Conte, J. E., Jr., E. Lin, and E. Zurlinden. 2000. High-performance liquid chromatographic determination of pyrazinamide in human plasma, bronchoalveolar lavage fluid, and alveolar cells. J. Chromatogr. Sci. 38:33-37.
15. Craig, W. A. 2007. Pharmacodynamics of antimicrobials: general concepts and applications, p. 1-19. In C. H. Nightangle, P. G. Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmacodynamics in theory and practice. Informa Healthcare USA, Inc., New York, NY.
16. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles.
17. Deziel, M. R., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Basset, L. Miller, K. Bush, M. Kelly, and G. L. Drusano. 2005. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
18. Dickinson, J. M., and D. A. Mitchison. 1991. Efficacy of intermittent pyrazinamide in experimental murine tuberculosis. Tubercle 72:110-114.
19. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
20. Grosset, J., C. Truffot-Pernot, C. Lacroix, and B. Ji. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. 36:548-551.
21. Gumbo, T., A. Louie, M. R. Deziel, and G. L. Drusano. 2005. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob. Agents Chemother. 49:3178-3181.
22. Gumbo, T., A. Louie, M. R. Deziel, W. Liu, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788.
23. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
24. Gumbo, T., A. Louie, W. Liu, P. G. Ambrose, S. M. Bhavnani, D. Brown, and G. L. Drusano. 2007. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 195:194-201.
25. Gumbo, T., A. Louie, W. Liu, D. Brown, P. G. Ambrose, S. M. Bhavnani, and G. L. Drusano. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51:2329-2336.
26. Heifets, L., and P. Lindholm-Levy. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis. 145:1223-1225.
27. Heifets, L., and T. Sanchez. 2000. New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 38:1498-1501.
28. Iseman, M. D. 2000. Tuberculosis chemotherapy, including directly observed therapy, p. 271-321. In A clinician's guide to tuberculosis. Lippincott Williams & Wilkins, Philadelphia, PA.
29. Jayaram, R., S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R. K. Shandil, E. Kantharaj, and V. Balasubramanian. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
30. Jayaram, R., R. K. Shandil, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, E. Kantharaj, and V. Balasubramanian. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957.
31. Jindani, A., V. R. Aber, E. A. Edwards, and D. A. Mitchison. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949.
32. Jindani, A., C. J. Dore, and D. A. Mitchison. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167:1348-1354.
33. Kiem, S., and J. J. Schentag. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob. Agents Chemother. 52:24-36.
34. Konno, K., H. Nagayama, and S. Oka. 1959. Nicotinamidase in mycobacteria: a method for distinguishing bovine type tubercle bacilli from other mycobacteria. Nature 184(Suppl. 22):1743-1744.
35. Kubendiran, G., C. N. Paramasivan, S. Sulochana, and D. A. Mitchison. 2006. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J. Chemother. 18:617-623.
36. Lister, P. D., A. M. Prevan, and C. C. Sanders. 1997. Importance of betalactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitordrug combinations: studies with piperacillin-tazobactam and piperacillinsulbactam. Antimicrob. Agents Chemother. 41:721-727.
37. Mackaness, G. B. 1956. The intracellular activation of pyrazinamide and nicotinamide. Am. Rev. Tuberc. 74:718-728.
38. McDermott, W., and R. Tompsett. 1954. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 70:748-754.
39. McDowell, M. A., C. D. Fryar, R. Hirsch, and C. L. Ogden. 2005. Anthropometric reference data for children and adults: U.S. population, 1999-2002. Report 361. National Center for Health Statistics, Hyattsville, MD.
40. Mitchison, D. A. 1979. Basic mechanisms of chemotherapy. Chest 76:771-781.
41. Mitchison, D. A. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219-225.
42. Nguyen, D., P. Brassard, J. Westley, L. Thibert, M. Proulx, K. Henry, K. Schwartzman, D. Menzies, and M. A. Behr. 2003. Widespread pyrazinamideresistant Mycobacterium tuberculosis family in a low-incidence setting. J. Clin. Microbiol. 41:2878-2883.
43. Peloquin, C. A., G. S. Jaresko, C. L. Yong, A. C. Keung, A. E. Bulpitt, and R. W. Jelliffe. 1997. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41:2670-2679.
44. Raynaud, C., M. A. Laneelle, R. H. Senaratne, P. Draper, G. Laneelle, and M. Daffe. 1999. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 145(Pt 6):1359-1367.
45. Salfinger, M., and L. B. Heifets. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob. Agents Chemother. 32:1002-1004.
46. Schwartz, W. S., and R. E. Moyer. 1954. The chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or isoniazid. Am. Rev. Tuberc. 70:413-422.
47. Scorpio, A., and Y. Zhang. 1996. Mutations in pncA, a gene encoding pyrazinamidase/ nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667.
48. Snider, D. E., Jr., J. Rogowski, M. Zierski, E. Bek, and M. W. Long. 1982. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland. Am. Rev. Respir. Dis. 125:265-267.
49. Steenken, W., Jr., and E. Wolinsky. 1954. The antituberculous activity of pyrazinamide in vitro and in the guinea pig. Am. Rev. Tuberc. 70:367-369.
50. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, and G. L. Drusano. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 51:744-747.
51. Victor, T. C., E. M. Streicher, C. Kewley, A. M. Jordaan, G. D. van der Spuy, M. Bosman, H. Louw, M. Murray, D. Young, P. D. van Helden, and R. M. Warren. 2007. Spread of an emerging Mycobacterium tuberculosis drugresistant strain in the western Cape of South Africa. Int. J. Tuberc. Lung Dis. 11:195-201.
52. Wilkins, J. J., G. Langdon, H. McIlleron, G. C. Pillai, P. J. Smith, and U. S. Simonsson. 2006. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur. J. Clin. Pharmacol. 62:727-735.
53. Woo, J., W. Cheung, R. Chan, H. S. Chan, A. Cheng, and K. Chan. 1996. In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein. Clin. Biochem. 29:175-177.
54. Yeager, R. L., W. G. Munroe, and F. I. Dessau. 1952. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65:523-546.
55. Zhang, Y., S. Permar, and Z. Sun. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
56. Zhang, Y., A. Scorpio, H. Nikaido, and Z. Sun. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181:2044-2049.
57. Zhang, Y., M. M. Wade, A. Scorpio, H. Zhang, and Z. Sun. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52:790-795.
58. Zhu, M., J. R. Starke, W. J. Burman, P. Steiner, J. J. Stambaugh, D. Ashkin, A. E. Bulpitt, S. E. Berning, and C. A. Peloquin. 2002. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 22:686-695.
59. Zimhony, O., J. S. Cox, J. T. Welch, C. Vilcheze, and W. R. Jacobs, Jr. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6:1043-1047.
60. Zimhony, O., C. Vilcheze, M. Arai, J. T. Welch, and W. R. Jacobs, Jr. 2007. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrob. Agents Chemother. 51:752-754.